CITIUS ONCOLOGY, INC. Net Income Loss

Quick Answer

CITIUS ONCOLOGY, INC. reported Net Income Loss of -$24.76 million for the year ending 2025.

  • CITIUS ONCOLOGY, INC. showed a decrease of -17.1% in Net Income Loss from 2024 to 2025.
  • This data is from CITIUS ONCOLOGY, INC.'s annual report (Form 10-K), filed with the SEC on December 23, 2025.
  • XBRL data for this metric is available from 2022 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 5 years of available data (2022 to 2025), CITIUS ONCOLOGY, INC.'s Net Income Loss has declined by 6,602.3%.
  • Historical annual values: Fiscal year 2025: -$24.76 million | Fiscal year 2024: -$21.15 million | Fiscal year 2023: $2.42 million | Fiscal year 2023: -$12.70 million | Fiscal year 2022: $380.8 thousand.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: